Table 3.
Factors associated with IPT adherence among HIV-positive patients in Gondar, 2016
| Variables | Adherence
|
OR (95% CI)
|
||
|---|---|---|---|---|
| Yes | No | Crude | Adjusted | |
| Sex | ||||
| Male | 73 | 7 | 0.79 (0.27–2.30) | 1.39 (0.20–9.56) |
| Female | 66 | 8 | 1 | 1 |
| Age | ||||
| 18–30 | 75 | 9 | 1 | 1 |
| 31–40 | 46 | 5 | 2.16 (0.26–18.16) | 1.16 (0.23–5.92) |
| .40 | 18 | 1 | 1.96 (0.21–17.92) | 0.44 (0.34–6.50) |
| Occupation | ||||
| Self-employed | 52 | 4 | 1 | 1 |
| Government employer | 21 | 5 | 1.24 (0.28–5.35) | 1.38 (0.18–10.23) |
| Housewives | 31 | 2 | 0.66 (0.11–3.84) | 0.38 (0.03–4.37) |
| Merchants | 33 | 4 | 2.44 (0.59–10.05) | 3.941 (0.29–52.95) |
| Students | 2 | 0 | 0.000 | 0.000 |
| Duration of IPT | ||||
| 1–2 months | 39 | 6 | 1 | 1 |
| ≥3 months | 100 | 9 | 2.48 (0.37–18.26) | 0.09 (0.10–0.79) |
| Explanation about IPT regimen | ||||
| Yes | 105 | 13 | 1 | 1 |
| No | 34 | 2 | 0.47 (0.10–2.21) | 0.26 (0.23–3.12) |
| INH may be dangerous to your health | ||||
| Strongly disagree | 33 | 3 | 1 | 1 |
| Strongly agree | 4 | 3 | 8.5 (1.64–44.03) | 9.44 (0.62–128.48) |
| Do not know | 102 | 9 | 1.09 (0.28–4.30) | 2.45 (0.37–15.99) |
| Chance of getting sick from TB without treatment | ||||
| High | 107 | 17 | 1 | 1 |
| Average/below average | 19 | 0 | 1.26 (0.25–6.43) | 8.79 (0.85–91.08) |
| Do not know | 13 | 2 | 0.00 | 0.00 |
| Side effects | ||||
| Yes | 45 | 3 | 0.24 (0.07–0.74) | 0.64 (0.27–10.03) |
| No | 100 | 6 | 1 | 1 |
| ART status | ||||
| Pre-ART | 16 | 8 | 0.24 (0.07–0.73) | 1.68 (0.27–10.03) |
| On ART | 109 | 21 | 1 | 1 |
| ART regimen | ||||
| AZT+3TC+NVP | 85 | 8 | 1 | 1 |
| AZT+3TC+EFV | 15 | 4 | 0.84 (0.16–4.33) | 0.08 (0.003–2.17) |
| TDF+3TC+NVP | 11 | 1 | 0.429 (0.03–5.12) | 0.144 (0.015–1.42) |
| TDF+3TC+EFV | 18 | 12 | 2.4 (0.38–14.97) | 1.114 (0.09–13.21) |
| INH makes me tired | ||||
| Yes | 79 | 11 | 0.48 (0.14–1.58) | 1.59 (0.27–9.42) |
| No | 60 | 4 | 1 | 1 |
Abbreviations: AZT, zidovudine; ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; OR, overall ratio; INH, isonizid; IPT, isoniazid preventive therapy; NVP, nevirapine; TB, tuberculosis; TC, lamivudine; TDF, tenofovir.